Vercef DS Powder for Suspension
Cefpodoxime
80mg/5ml
Beximco Pharmaceuticals Ltd.
| Pack size | 50ml bot |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 175.00 AED |
Indications
Vercef DS Powder for Suspension is used for:
Pharyngitis, Acute otitis media, Community-acquired pneumonia, Sinusitis, UTI, Cystitis, Gonorrhea, Skin and skin structure infections, Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Acute bacterial exacerbation of chronic bronchitis
Adult Dose
Acute Bronchitis & Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis
200 mg PO q12hr for 10 days
Acute Community-Acquired Pneumonia
200 mg PO q12hr for 14 days
Pharyngitis/Tonsillitis
100 mg PO q12hr for 5-10 days
Skin/Skin Structure Infections
400 mg PO q12hr for 7-14 days
Uncomplicated gonorrhoea
Acute, uncomplicated urethral and cervical gonorrhea
200 mg as a single dose
Uncomplicated Urinary Tract Infections
100 mg PO q12hr for 7-14 days
Child Dose
Child:
General Dosage Range
<2 months: Safety and efficacy not established
2 months to 12 years: 5 mg/kg PO q12hr; not to exceed 200 mg/dose
>12 years: 100-400 mg PO q12hr
Acute Maxillary Sinusitis
<2 months: Safety and efficacy not established
2 months-12 years: 5 mg/kg PO q12hr for 10 days; individual doses not to exceed 200 mg
>12 years: 200 mg PO q12hr for 10 days
Acute Otitis Media
<2 months: Safety and efficacy not established
2 months-12 years: 5 mg/kg PO q12hr for 5 days; individual doses not to exceed 200 mg
>12 years: 200 mg PO q12hr for 5 days
Pharyngitis/Tonsillitis
<2 months: Safety and efficacy not established
2 months-12 years: 5 mg/kg PO q12hr for 5-10 days; individual doses not to exceed 100 mg
>12 years: 100 mg PO q12hr for 5-10 days
Chronic Bronchitis, Bacterial Exacerbation
>12 years: 200 mg PO q12hr for 10 days
Cystitis, Acute Uncomplicated
>12 years: 100 mg PO q12hr 5-7 days
Acute Community-Acquired Pneumonia
200 mg PO q12hr for 14 days
Renal Dose
Renal impairment
CrCl <30 mL/min: Give q24hr
Hemodialysis: Give 3 times weekly after dialysis
Administration
Should be taken with food. Take after meals.
Reconstitution: Reconstitute powd for oral susp at the time of dispensing by adding the amount of water specified on the container to provide a susp containing 50 mg or 100 mg per 5 mL. Add water in 2 equal parts and shake the bottle vigorously after each addition.
Contra Indications
Hypersensitivity.
Precautions
Reduce dosage by 50% if CrCl is 10-30 mL/min and by 75% if CrCl is <10 mL/min (high dosages may cause CNS toxicity)
Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy
Use with caution in patients with history of penicillin allergy
Use caution in patients with history of beta-lactam allergy, especially IGE mediated reactions, including angioedema, anaphylaxis, urticaria)
Some dosage forms may contain the metabolite of benzyl alcohol benzoic acid; large amounts of benzyl alcohol associated with potentially fatal toxicity (gasping syndrome) in neonates; avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates
Pregnancy-Lactation
Pregnancy category: B
Lactation: Drug excreted in breast milk in low concentrations; not recommended
Interactions
Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti cholinergics (e.g., propantheline) delay peakn plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC).
Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.
Nephrotoxic drugs: Although nephrotoxicity has not been noted when cefpodoxime proxetil was given alone, close monitoring of renal function is advised when cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.
Potentially Fatal: Monitor renal function during admin. Additive nephrotoxic effects with furosemide.
Contraindicated (0)
Serious (3)
BCG vaccine live
cholera vaccine
microbiota oral
Adverse Effects
Side effects of Cefpodoxime :
>10%
Diarrhea in infants and toddlers (15.4%),Diaper rash (12.1%)
1-10%
Diarrhea (7.4%),Nausea (3.8%),Vaginal infection (3.1%),Vomiting (1.1-2.1%),Abdominal pain (1.6%),Rash (1.4%),Headache (1.1%)
Potentially Fatal: Pseudomembranous colitis; nephrotoxicity.
Mechanism of Action
Cefpodoxime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Note
Vercef DS 80mg/5ml Powder for Suspension manufactured by Beximco Pharmaceuticals Ltd.. Its generic name is Cefpodoxime. Vercef DS is availble in Bangladesh.
Farmaco BD drug index information on Vercef DS Powder for Suspension is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.